TriSalus Life Sciences (NASDAQ:TLSIW) Shares Rise 18.2%

The medical device company's stock surged after a trading update.

Mar. 21, 2026 at 1:08am

Got story updates? Submit your updates here. ›

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) jumped 18.2% during mid-day trading on Wednesday, reaching a high of $1.48 before closing at $1.75. The company, which is focused on developing minimally invasive cancer radiation therapy technologies, saw trading volume decline 56% from the average session.

Why it matters

TriSalus Life Sciences is a clinical-stage medical device company working on innovative cancer treatment solutions. The significant stock price increase suggests investor confidence in the company's technology and future prospects.

The details

TriSalus Life Sciences' lead product is the TriMark™ Tissue Marker System, designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. The company aims to improve treatment planning, patient comfort and long-term follow-up imaging through its platform approach to oncology treatment.

  • TriSalus Life Sciences' share price traded up 18.2% during mid-day trading on Wednesday, March 21, 2026.
  • The stock reached a high of $1.48 and closed at $1.75 on March 21, 2026.

The players

TriSalus Life Sciences, Inc.

A clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy.

Cerity Partners LLC

A hedge fund that acquired a new position in shares of TriSalus Life Sciences in the 4th quarter.

Citadel Advisors LLC

A hedge fund that grew its stake in TriSalus Life Sciences by 439% during the third quarter.

Fort Baker Capital Management LP

A hedge fund that acquired a new stake in TriSalus Life Sciences in the fourth quarter.

Aristeia Capital L.L.C.

A hedge fund that bought a new stake in TriSalus Life Sciences in the fourth quarter.

Got photos? Submit your photos here. ›

The takeaway

The significant stock price increase for TriSalus Life Sciences suggests investors are optimistic about the company's innovative cancer treatment technologies and their potential to improve patient outcomes.